OncoMatch/Clinical Trials/NCT06445062
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Official title: A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Is NCT06445062 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies multiple treatments for colorectal cancer.
Treatment: RMC-6236 · mFOLFOX6 regimen · bevacizumab · mFOLFIRINOX regimen · cetuximab · gemcitabine · nab-paclitaxel · RMC-9805 · FOLFIRI regimen — The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol G: RMC-9805 + cetuximab + FOLFIRI
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Colorectal Cancer
Pancreatic Cancer
Gastric Cancer
Hepatocellular Carcinoma
Cholangiocarcinoma
Esophageal Carcinoma
Biomarker criteria
Required: KRAS g12d
Required: KRAS mutation
Disease stage
Metastatic disease required
metastatic disease; documented unresectable or metastatic disease
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ironwood Cancer and Research Centers · Chandler, Arizona
- Mayo Clinic Hospital · Phoenix, Arizona
- HonorHealth Research Institute · Scottsdale, Arizona
- UC San Diego Moores Cancer Center · La Jolla, California
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06445062 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require KRAS?
Yes, KRAS g12d is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify